In the afternoon, the biomedical sector rose sharply, led by CXO, with Pharmaron Beijing Co., Ltd.*, Kangtai Bio, Wuxi Apptec, Kailiying up more than 7%, Shanghai Fosun Pharmaceutical and Zhifei Bio up more than 5%.$biological drug ETF (159839.SZ) $、$Precision Medical LOF (501005.SH) $、$biotechnology LOF (501009.SH) $They all rose more than 3% in intraday trading.

On March 22nd, the relevant departments issued the third edition of the guidelines for the screening of Regional novel coronavirus Nucleic Acid testing organizations. Guide all localities to do a good job in the prevention and control of COVID-19 's epidemic situation. Prior to this, National Healthcare Security Administration also issued a notice on effectively doing a good job in medical security for the prevention and control of the current epidemic, clearly requiring all provinces to temporarily include novel coronavirus antigen testing reagents and corresponding testing items in their province's basic medical insurance catalogue in accordance with procedures. Related COVID-19 testing, vaccines, drugs and upstream industry chain (CXO) is expected to continue to benefit.

Shen Wanhongyuan Securities pointed out that the current domestic epidemic is still showing a multi-point outbreak. Under the policy of dynamic zero clearance, China has recently opened up COVID-19 antigen testing channels, while approving Pfizer Inc Paxlovid import registration. A number of domestic companies are also involved in the upstream production and domestic commercialization of the drug. It is recommended to pay attention to COVID-19 Industrial chain Company under the current epidemic situation.

Biomedicine ETF (159839) tracks the biomedical index (399441), fixed 30 constituent stocks, gives priority to the allocation of biomedical industry leaders, and has significant advantages.